Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
CA 2001884 A1 · Owner: Peets, Edwin A. · Inventors: Peets, Edwin A.; Tanner, Daniel J.; Smiles, Kenneth A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Condylomata acuminata infections (anogenital warts) are treated in infected patients by use of a combined therapy, i.e. by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks. The pharmaceutical composition of interferon for use in the combined therapy contains recombinant DNA human interferon alfa-2b in which 1.0 X 106 International Units are administered by injection to each lesion. The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means. The use of human alpha interferon for the manufacture of a medicament for use in the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 31, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 31, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 31, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.